Article

Second Annual "Giants of Cancer Care" Announced

Author(s):

Premier Awards Program Presented by OncLive Names 2014 Cancer Care Luminaries

Plainsboro, N.J. — May 30, 2014 – OncLive today announced the 2014 Giants of Cancer Care, 16 heroes in the oncology field whose careers have been dedicated to improving or prolonging the lives of those with cancer. The second annual Giants of Cancer Care class will be honored during a special reception tonight in Chicago.

The Giants program is presented by OncLive, the official website for OncologyLive, Oncology & Biotech News, Urologists in Cancer Care, Oncology Nursing News, Oncology Business Management and Contemporary Oncology. Giants are chosen by an exclusive advisory board of oncology educators, clinicians and researchers. The Giants Advisory Board is chaired by Hope S. Rugo, M.D., professor of medicine, director of breast oncology and clinical trials education at the University of California, San Francisco. Corporate sponsors of the program include Bayer Healthcare Pharmaceuticals.

“After 30+ years in medical publishing, it became apparent to me there was a lack of recognition for the unsung heroes in the oncology field,” said OncLive Chairman and CEO Mike Hennessy. “The Giants of Cancer Care program is our way of giving back to the oncologists that give us so much. We’re tremendously grateful to the 2014 class.”

Giants of Cancer Care are selected based on their professional achievements, specific contributions to their respective area of expertise, and the overall impact of their work as it relates to oncology as a whole.

The 2014 Giants of Cancer Care

Breast Cancer: Dennis J. Slamon, M.D., Ph.D., University of California, Los Angeles

Gastrointestinal Cancer: George D. Demetri, M.D., Ph.D., Dana-Farber Cancer Institute

Genetics: Janet Davison Rowley, M.D., University of Chicago (deceased)

Genitourinary Cancer: Philip W. Kantoff, M.D., Dana-Farber Cancer Institute

Head & Neck Cancer: Kie Kian Ang, M.D., MD Anderson Cancer Center (deceased)

Leukemia: Hagop M. Kantarjian, M.D., MD Anderson Cancer Center

Lung Cancer: Paul A. Bunn Jr., M.D., University of Colorado Cancer Center

Lymphoma: Riccardo Dalla-Favera, M.D., Columbia University Medical Center

Melanoma: Jedd D. Wolchok, M.D., Ph.D., Memorial Sloan Kettering Cancer Center

Myeloma: Kenneth C. Anderson, M.D., Dana-Farber Cancer Institute

Prostate Cancer: Patrick C. Walsh, M.D., Johns Hopkins University

Scientific Advances: James P. Allison, Ph.D., MD Anderson Cancer Center

Education: John R. Seffrin, Ph.D., American Cancer Society

Supportive Care: Jimmie C. Holland, M.D., Memorial Sloan Kettering Cancer Center

Drug Development: Howard A. Burris III, M.D., Sarah Cannon Research Institute

Outreach: Edith A. Perez, M.D., Mayo Clinic

Each Giant will be individually profiled in a special edition of OncologyLive and prominently featured on OncLive.com. To learn more about the Giants of Cancer Care program, visit giants.onclive.com.

###

About OncLive®

OncLive.com is the official web portal for Intellisphere’s Oncology Specialty Group, which publishes OncologyLive, Oncology & Biotech News, Oncology Nursing News, Urologists in Cancer Care, Oncology Business Management and Contemporary Oncology. The mission of OncLive® and its family of publications is to provide oncology professionals with the resources and information they need to provide the best care for their patients. The Oncology Specialty Group is a division of Intellisphere, LLC, a leading provider of healthcare publishing, research, and education. To learn more, please visit www.OncLive.com.

Media Contact:

Courtney Dysart

Courtney@hornercom.com

267-932-8760 ext. 300

Related Videos
Andrew Ip, MD
Mansi R. Shah, MD
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
3 experts are featured in this series.
Sangeetha Venugopal, MD, MS, discusses factors that inform JAK inhibitor selection in myelofibrosis.
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
2 experts in this video